REAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Real Brokerage Inc (REAX) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators, options sentiment, and financial performance suggest a cautious approach. While there are positive catalysts, such as revenue growth and new agent acquisitions, the negative catalysts, including declining profitability, hedge fund selling, and mixed analyst ratings, outweigh the positives. A 'hold' recommendation is appropriate until clearer bullish signals emerge.
The MACD histogram is positive at 0.0342, indicating slight bullish momentum, but RSI is neutral at 43.887, showing no strong trend. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key resistance levels (R1: 2.901, R2: 3.027), suggesting limited upward momentum in the short term.
Q4 revenue increased by 44.1% YoY, showing strong top-line growth.
The Sandra Rathe Team joined Real, enhancing its presence in South Florida.
Analysts like JonesResearch and Freedom Capital maintain a Buy rating, citing the company's asset-light model and growth potential.
Hedge funds are aggressively selling, with a 7652.27% increase in selling over the last quarter.
Declining profitability metrics, including a 36.73% drop in net income and a 33.33% drop in EPS YoY.
Zelman downgraded the stock to Neutral, and BTIG reduced the price target to $4.50 from $6, citing multiple compression in the real estate sector.
In Q4 2025, revenue grew by 30.17% YoY to $39.03 million, but net income dropped by 36.73% to -$4.2 million. EPS decreased by 33.33% to -$0.02, and gross margin fell significantly by -1194.10% YoY, indicating declining profitability despite revenue growth.
Analyst sentiment is mixed. Zelman downgraded the stock to Neutral with a $3 price target. BTIG lowered its price target to $4.50 from $6 but maintained a Buy rating. JonesResearch and Freedom Capital remain bullish, citing oversold conditions and growth potential, with price targets of $5 and $4.70, respectively.
